Search alternatives:
significantly mean » significantly less (Expand Search), significantly mediate (Expand Search), significantly impact (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), clinical areas (Expand Search)
linear decrease » linear increase (Expand Search)
Showing 41 - 60 results of 7,697 for search '(( significantly mean decrease ) OR ( significant ((clinical decrease) OR (linear decrease)) ))', query time: 0.51s Refine Results
  1. 41
    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups.

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 42
    Time course of best-corrected visual acuity (BCVA) in all eyes.

    Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 43
    Annual number of outpatient visits in recurrence and non-recurrence groups.

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 44
    Time course of central retinal thickness (CRT) in all eyes.

    Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 45
    Annual treatment frequencies in all eyes.

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 46
    Annual treatment frequencies in recurrence and non-recurrence groups.

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 47
    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups.

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 48
    Preoperative background characteristics of the patients.

    Preoperative background characteristics of the patients. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 49
    Changes in clinical variables.

    Changes in clinical variables. by Karel Joineau (21799908)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 50
    Demographic and clinical data at baseline.

    Demographic and clinical data at baseline. by Karel Joineau (21799908)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 51
    The demographical and clinical characteristics of subjects at baseline.

    The demographical and clinical characteristics of subjects at baseline. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 52
    Clinical and demographic characteristics of the participants.

    Clinical and demographic characteristics of the participants. by María Benito-de-Pedro (22057468)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 53
    Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)).

    Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (sign... by Mobina Faqani (22783963)

    Published 2025
    Save to List
    Saved in:
  14. 54
    Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period.

    Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period. by Jelena Filimonovic (22305307)

    Published 2025
    Save to List
    Saved in:
  15. 55
    IFA significantly attenuated capsule-mediated resistance to the binding of C3b and C5b-9 to bacterial surface.

    IFA significantly attenuated capsule-mediated resistance to the binding of C3b and C5b-9 to bacterial surface. by Tingting Wang (123983)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 56
    The correlation between clinical presentations and baseline serum inflammatory cytokines before TFESI.

    The correlation between clinical presentations and baseline serum inflammatory cytokines before TFESI. by Pornpan Chalermkitpanit (22110121)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 57
    Estimated mean values for light interception.

    Estimated mean values for light interception. by Torsten Schober (20485754)

    Published 2024
    “…An increase in PD led to a linear decrease in inflorescence yield per plant (<i>p</i> = 0.02), whereas a positive linear relationship was found for inflorescence yield (<i>p</i> = 0.0001) and CBD yield (<i>p</i> = 0.0002) per m<sup>2</sup>. …”
    Save to List
    Saved in:
  18. 58
    Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment.

    Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 59
    Flowchart of patient selection in this study.

    Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 60
    Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment.

    Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: